Client Overview
A pharmaceutical company operating in the generic medicinal product segment needed to transfer its Marketing Authorization to a new Local Representative (LR) in Mexico — a process that, under COFEPRIS, requires technical precision, local legal standing, and active pharmacovigilance representation. Without an in-country regulatory infrastructure of its own, the client needed a partner capable of executing the transfer end-to-end while ensuring the product never left the market. The stakes were straightforward but significant: an MA transfer that stalls or generates objections puts commercial continuity at direct risk. Freyr LATAM was engaged to own the process from gap analysis to approved transfer.
Background
In Mexico, transferring a Marketing Authorization to a new Local Representative involves more than updating a record. COFEPRIS requires a complete review of the dossier under current standards, validation of all technical documents and labeling, verified legal representation, and an active pharmacovigilance unit in-country. Any gap in these requirements can trigger a formal objection — restarting the clock and creating the kind of regulatory limbo that directly impacts product availability.
For generic drug companies, where market position depends heavily on uninterrupted supply, that risk is not abstract. The operational pressure to complete the transfer cleanly — on the first submission cycle — defines what a successful engagement looks like.
Services in Scope
Detailed review of existing dossier against current
COFEPRIS format and content requirements
Identification and remediation of deficiencies before submission
Full dossier alignment with COFEPRIS technical and labeling standards
Validation of all regulatory components under updated national guidelines
Formal execution of the MA transfer to the new Local Representative in Mexico
End-to-end submission management targeting first-cycle approval
Legal representation in Mexico for regulatory compliance purposes
Pharmacovigilance Unit (PVU) representation to meet COFEPRIS mandatory requirements
Challenge
The challenge in this engagement was not complexity for its own sake — it was the interdependency of requirements that individually seemed manageable but collectively created a high-pressure execution environment.
Regulatory variability: Document types and formats required for an MA transfer are not uniformly specified — COFEPRIS expectations can vary across product categories, and misreading those expectations at submission is a costly mistake.
Technical document validation: Labeling and technical dossier components needed thorough in-depth validation — not a checklist review, but a substantive alignment exercise against current COFEPRIS standards.
Absence of in-country representation: Without a local legal representative or PVU already in place, the transfer could not proceed — making the establishment of both a prerequisite condition, not a parallel activity.
Market continuity risk: Every day the transfer remained unresolved created exposure. Delays in the approval process translate directly into uncertainty around commercial availability — a risk the client could not absorb.
Solution
1
Freyr LATAM initiated the engagement with a detailed documentation gap analysis — mapping every component of the existing dossier against COFEPRIS's current requirements and establishing a structured remediation plan to close deficiencies before submission.
2
The team prepared the full MA transfer dossier in alignment with COFEPRIS format and technical standards, including labeling validation and content review across all required document types.
3
Freyr established legal representation in Mexico on behalf of the client, fulfilling the mandatory local legal presence requirement and enabling the formal transfer process to proceed without interruption.
4
Freyr assumed Pharmacovigilance Unit (PVU) responsibilities, ensuring that pharmacovigilance compliance was in place and documented at the time of submission — removing a critical prerequisite risk from the timeline.
5
The MA transfer was formally executed and submitted to COFEPRIS as a complete, objection-ready package — structured for first-cycle approval with no gaps that could trigger a request for additional information.
Impact
The Marketing Authorization was successfully transferred to the new Local Representative on the first submission cycle, with full COFEPRIS compliance and no disruption to the product's commercial availability in Mexico. By owning both the technical preparation and the local representation requirements, Freyr LATAM eliminated the two most common sources of delay in MA transfer processes — and positioned the client for continued regulatory operations in the market.
MA successfully transferred to a new Local Representative — first-cycle approval
Zero market disruption: product availability maintained throughout the transfer
Proactive gap analysis eliminated documentation deficiencies before submission
Legal representation and PVU coverage established for full COFEPRIS compliance
Reduced approval timeline through structured dossier preparation and validation
Strengthened regulatory foundation for continued operations in the Mexican market
